Lasa Supergenerics Limited

Lasa Supergenerics Board Approves 11th AGM, Director Re-appointment, and More

Lasa Supergenerics' Board approved the 11th AGM on September 30, 2026. Mr. Omkar Herlekar was re-appointed as Director. Janardan Savala appointed as Executive Director for 5 years from August 26, 2026. Donations up to ₹2 crore and managerial remuneration up to ₹3 crore were approved.

Lasa Supergenerics Board Approves 11th AGM, Director Re-appointment, and More

Lasa Supergenerics Limited's Board approved the 11th AGM on September 30, 2026. Key decisions include re-appointing Director Omkar Herlekar and appointing Janardan Savala as Executive Director for five years from August 26, 2026. The company will also seek shareholder approval for donations up to ₹2 crore annually and managerial remuneration up to ₹3 crore annually.

Lasa Supergenerics Appoints Janardan Kamlu Savala as Executive Director

Lasa Supergenerics Limited appointed Mr. Janardan Kamlu Savala as an Additional Director (Executive Director) following a Board Meeting on August 26, 2026. The appointment requires member approval. Savala has experience in business operations and banking processes.

Lasa Supergenerics: Whole-time Director Ganesh Potdar Resigns

Mr. Ganesh Potdar has resigned as Whole-time Director of Lasa Supergenerics Limited, effective August 25, 2026. His resignation is due to personal commitments.

Lasa Supergenerics: Board Meeting Approves Q1 FY27 Unaudited Financial Results

Lasa Supergenerics Limited's Board approved Q1 FY27 unaudited financial results on August 14, 2026. A fire incident on May 18, 2025, caused ₹2057.47 Lacs in damages, halting operations and impacting assets. The company faces operational challenges, GST disputes (₹3,810.93 Lacs), and has suspended grant income recognition.

Lasa Supergenerics Board Approves Unaudited Q1 FY27 Results, Notes Fire Impact

Lasa Supergenerics' Board approved Q1 FY27 unaudited results on August 14, 2026. The company is severely impacted by a May 2025 fire incident, resulting in operational halts and an unrecognized loss of ₹2057.47 Lakhs. Pending GST demands total ₹3,810.93 Lakhs. Operations remain suspended.

Lasa Supergenerics Files SDD Compliance Certificate for Q1 FY27

Lasa Supergenerics Limited submitted its SDD Compliance Certificate for the quarter ended June 30, 2026. The company confirmed it has a functional, secure, and non-tamperable Structured Digital Database in place, capturing all UPSI as per SEBI regulations. No non-compliance was reported.

Lasa Supergenerics Closes Trading Window for Q1 FY27 Results

Lasa Supergenerics Limited has closed its trading window for designated employees and relatives from July 01, 2026. The closure is in effect until 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026.

Lasa Supergenerics Promoter Omkar Herlekar Reports No New Share Encumbrance

Lasa Supergenerics promoter Omkar Herlekar declared no new share encumbrances for FY26. This annual disclosure, submitted on April 7, 2026, confirms no changes beyond previously disclosed holdings as per SEBI Takeover Regulations.

Lasa Supergenics: Annual Secretarial Compliance Report Highlights Non-Compliance

Lasa Supergenics Limited's Annual Secretarial Compliance Report for FY26 reveals multiple SEBI regulation breaches. Fines were levied for delayed appointment of a Compliance Officer and late submissions of Shareholding Pattern, shareholder complaints, and Corporate Governance Report for Q4 FY26. The company has since made these filings.

Lasa Supergenics Files Integrated Financial Results for Q4FY26; Auditor Issues Qualified Opinion

Lasa Supergenics Limited filed its Q4 FY26 integrated financial results on May 29, 2026. The company's audited financial results for the quarter and year ended March 31, 2026, were approved by the board. The statutory auditors issued a qualified opinion due to potential impairment of tangible and intangible assets.

Lasa Supergenerics Discloses Related Party Transactions for Q4FY26

Lasa Supergenerics Limited disclosed related party transactions for the quarter and year ended March 31, 2026. Total transactions amounted to ₹618 crore, with ₹35.36 crore in interest. Transactions include remuneration, sitting fees, and donations to related parties.

Lasa Supergenerics Board Approves Audited FY26 Results; Auditor Issues Qualified Opinion

Lasa Supergenerics Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a net loss before tax of ₹3,460.77 lakhs for the year. The Statutory Auditor issued a qualified opinion due to unresolved issues regarding the impairment of tangible and intangible assets following a fire incident and operational challenges.

Lasa Supergenics Board Approves Q4 FY26 Unaudited Results; Auditor Issues Qualified Opinion

Lasa Supergenics announced its Q4 FY26 unaudited financial results on May 29, 2026. The company reported a net loss for the quarter and year ended March 31, 2026. The Statutory Auditor issued a qualified opinion regarding the impairment of tangible and intangible assets, citing unresolved issues from a fire incident and lack of impairment assessment for intangibles. The company is also contesting GST demands totaling ₹3,810.93 lakhs.

Lasa Supergenerics: Certificate under SEBI (Depositories and Participants) Regulations, 2018 for Q4FY26

Lasa Supergenerics Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter and year ended March 31, 2026. The RTA confirmed dematerialization processing and cancellation of certificates.

LASA Supergenerics Files SDD Compliance Certificate for Q4 FY26

Lasa Supergenerics Limited filed its SDD Compliance Certificate for the quarter ended March 31, 2026. The company confirmed adherence to SEBI (Prohibition of Insider Trading) Regulations, 2015, with a functional and secure Structured Digital Database.

Lasa Supergenerics Declares Non-Applicability of Large Entities Framework

Lasa Supergenerics Limited declared it is outside the Large Corporate category as per SEBI's debt securities framework. The company submitted this declaration to BSE and NSE on April 16, 2026.

Lasa Supergenerics: Trading Window Closed for Q4FY26 Results

Lasa Supergenerics Limited will close its trading window from April 01, 2026. The closure is effective until 48 hours after the declaration of audited financial results for the quarter and year ended March 31, 2026.

Lasa Supergenics Q3 FY26 Results: Board Approves Unaudited Financials, Auditor Notes Fire Impact

Lasa Supergenerics Limited's Board approved unaudited Q3 FY26 financial results on Feb 13, 2026. A fire on May 18, 2025, caused uninsured losses of ₹1273.62 lakhs (inventories) and ₹700 lakhs (PPE). Operations remain halted, impacting going concern status. Dormant bank balances and unconfirmed fixed deposits were noted.

Lasa Supergenics: Board Approves Q3 FY26 Unaudited Results; Fire Incident Impacts Operations

Lasa Supergenics announced unaudited Q3 FY26 results approved by the board on Feb 13, 2026. A major fire on May 18, 2025, caused uninsured losses of ₹1,273.62 lakhs in inventory and ₹700 lakhs in plant & equipment, halting all operations. Management is exploring contract manufacturing or leasing.

Lasa Supergenerics Q3FY26 Results: Board Approves Unaudited Financials

Lasa Supergenerics Limited's Board approved Q3FY26 unaudited financial results on February 13, 2026. A fire incident on May 18, 2025, caused uninsured losses of ₹1,273.62 Lakhs in inventory and ₹700.00 Lakhs in plant & equipment, halting production. Dormant bank accounts and suspended revenue recognition were also noted.

Lasa Supergenerics Board Meeting: Approves Q3 FY26 Unaudited Results, Notes Fire Incident Impact

Lasa Supergenerics' Board approved Q3 FY26 unaudited results. A fire on May 18, 2025, caused uninsured losses of ₹1,273.62 Lakhs in inventories and ₹700.00 Lakhs in property, plant, and equipment, halting all operations. Management is exploring alternative manufacturing arrangements.

Lasa Supergenerics Ltd. Submits SDD Compliance Certificate for Q3 FY26

Lasa Supergenerics Limited submitted its SDD Compliance Certificate for the quarter ended December 31, 2025. The company confirmed adherence to SEBI (Prohibition of Insider Trading) Regulations, 2015, with a functional and secure Structured Digital Database. Two required events were captured during the quarter.

Lasa Supergenics: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Lasa Supergenics Limited received a certificate for the quarter ended December 31, 2025, under SEBI (Depositories and Participants) Regulations, 2018. The certificate confirms processing of dematerialized securities and substitution in the register of members.

Lasa Supergenerics Appoints Ganesh Suresh Potdar as Executive Director

Lasa Supergenerics Limited's Board of Directors approved the appointment of Mr. Ganesh Suresh Potdar as an Additional Director in the capacity of Executive Director. This appointment is effective from January 02, 2026, to January 01, 2030, and requires member approval. Mr. Potdar brings expertise in business operations and banking processes.

Lasa Supergenerics Closes Trading Window from Jan 1, 2026, for Q3 FY26 Results

Lasa Supergenerics Limited will close its trading window from January 1, 2026. The window will reopen 48 hours after the declaration of the Unaudited Financial Results for the quarter ended December 31, 2025. This is in compliance with insider trading regulations.

Lasa Supergenerics Appoints Mrs. Mitti Jain as Company Secretary & Compliance Officer

Lasa Supergenerics Limited appoints Mrs. Mitti Jain as Company Secretary and Compliance Officer, effective December 16, 2025. Mrs. Jain, an Associate Member of ICSI with 10 years of experience, will also be a Key Managerial Personnel.

Lasa Supergenerics: Whole-Time Director Prathmesh Chalke Resigns

Mr. Prathmesh Chalke has resigned as Whole-time Director of Lasa Supergenerics Limited. His resignation is effective from the closing hours of December 31st, 2025. He confirmed no other material reasons for his resignation.

Disclosure of Related Party Transactions for Quarter Ended September 30, 2025

Lasa Supergenerics disclosed related party transactions for the quarter and half year ended September 30, 2025, including director remuneration, sitting fees, and donations, as per SEBI regulations.

Lasa Supergenerics Board Approves Q2 FY26 Unaudited Financial Results Amidst Fire Incident Impact

Lasa Supergenerics board approved Q2 FY26 unaudited results showing significant losses due to a major uninsured fire in May 2025, halting production. Management is exploring alternative manufacturing options.

LASA Supergenerics Announces Financial Results for Quarter and Half Year Ended September 30, 2025

LASA Supergenerics announced its financial results for the quarter and half-year ending September 30, 2025. A fire incident at the factory impacted operations and financials. The management is exploring alternative manufacturing arrangements.

Lasa Supergenerics Board Approves Q2/H1 FY26 Results Amidst Uninsured Fire Loss and Going Concern Issues

Lasa Supergenerics approved Q2/H1 FY26 results showing a huge loss. An uninsured fire on May 18, 2025, destroyed its main factory, halting production and raising going concern doubts.

LASA Supergenerics Approves Unaudited Financial Results for Quarter Ended September 30, 2025

LASA Supergenerics approves unaudited financial results for the quarter ended September 30, 2025. A fire incident caused significant damage, impacting operations and financials.

SDD Compliance Certificate for Quarter Ended September 30, 2025

Lasa Supergenerics Limited submitted SDD Compliance Certificate for the quarter ended September 30, 2025, in accordance with SEBI regulations, confirming the maintenance of a structured digital database.

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Lasa Supergenerics submitted a certificate under SEBI regulations for the quarter ended September 30, 2025, confirming the dematerialization of securities.

Lasa Supergenerics: Summary of 10th AGM held on 30 Sep 2025

Lasa Supergenerics: Company Secretary Resigns Citing Non-Operational Status

LASA Supergenerics Approves Unaudited Results for Quarter Ended June 2025

Lasa Supergenerics Approves AGM Notice, Director Re-appointment

LASA: Prathmesh Chalke Appointed as Executive Director

LASA Supergenerics: Company Secretary Mitti Jain Resigns

Lasa Supergenerics Appoints Four New Independent Directors to its Board

LASA seeks shareholder nod for appointment of Prathamesh Chalke as Executive Director

Independent Director Manali Bhagtani Resigns from Lasa Supergenerics

Independent Director Hardesh Tolani Resigns from Lasa Supergenerics Citing Non-Operational Status

Lasa Supergenerics Independent Director Resigns Citing Non-Operational Status